Holen Sie sich die Stockscreener-App
1.75
0.00%
0.00
Handel nachbörslich:
1.83
0.08
+4.57%
Schlusskurs vom Vortag:
$1.75
Offen:
$1.71
24-Stunden-Volumen:
2.58M
Relative Volume:
2.50
Marktkapitalisierung:
$118.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-1.1076
EPS:
-1.58
Netto-Cashflow:
$-27.38M
1W Leistung:
+34.62%
1M Leistung:
+29.63%
6M Leistung:
+10.76%
1J Leistung:
-37.50%
1-Tages-Spanne:
$1.67
$2.05
1-Wochen-Bereich:
$1.27
$2.05
52-Wochen-Spanne:
$0.8301
$2.90
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Firmenname
Regulus Therapeutics Inc
Sektor
Branche
Telefon
858-202-6300
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Vergleichen Sie RGLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.75 | 118.24M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.36B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.95B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.13B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-18 | Eingeleitet | Leerink Partners | Outperform |
| 2018-03-28 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-06 | Bestätigt | Wedbush | Outperform |
| 2017-01-30 | Herabstufung | Needham | Buy → Hold |
| 2017-01-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-11-02 | Bestätigt | Needham | Buy |
| 2016-07-25 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | FBR Capital | Outperform |
| 2016-06-28 | Bestätigt | Needham | Buy |
| 2016-06-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-04-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2015-04-21 | Fortgesetzt | FBR Capital | Outperform |
| 2014-11-24 | Eingeleitet | Deutsche Bank | Buy |
| 2014-08-07 | Bestätigt | FBR Capital | Outperform |
| 2013-08-14 | Bestätigt | Needham | Buy |
Alle ansehen
Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - Marketscreener.com
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo Finance
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
Regulus: Q4 Earnings Snapshot - Bakersfield.com
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR.com
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR.com
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Management Takes Center Stage at Major Healthcare ConferenceKey Details Inside - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Insider Moves Spark Interest: Is Regulus Therapeutics Set for a Comeback? - Jomfruland.net
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance
Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regulus Therapeutics Inc-Aktie (RGLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BALTIMORE DAVID | Director |
Jan 30 '25 |
Buy |
1.06 |
19,610 |
20,787 |
22,169 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 13 '25 |
Sale |
1.26 |
38,547 |
48,693 |
54,634 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
49,546 |
| Hagan Joseph P | Chief Executive Officer |
Jan 13 '25 |
Sale |
1.26 |
115,290 |
145,634 |
222,572 |
| Hagan Joseph P | Chief Executive Officer |
Jan 14 '25 |
Sale |
1.26 |
11,764 |
14,860 |
210,808 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 13 '25 |
Sale |
1.26 |
38,716 |
48,906 |
50,566 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
45,478 |
| Klassen Preston | President & Head of R & D |
Jan 13 '25 |
Sale |
1.26 |
31,445 |
39,721 |
36,055 |
| Collier Kathryn J | Director |
Jul 25 '24 |
Buy |
1.82 |
4,000 |
7,280 |
6,740 |
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):